Brimonidine in Rosacea

Sponsor

Cairo University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05401422

Collaborator

(none)

Enrollment

Arms

3.7

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Rosacea is a chronic and relapsing inflammatory cutaneous disorder with highly variable prevalence worldwide.

Condition or Disease	Intervention/Treatment	Phase
Rosacea	Other: treatment	N/A

Detailed Description

In our study, we will compare the safety, efficacy, and adverse effects of low-dose oral doxycycline alone versus combined with pulsed dye laser or topical brimonidine in treating erythematotelangiectatic rosacea in an attempt to build a treatment strategy in a disease with complex pathogenesis.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

45 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Efficacy and Safety of Combining Doxycycline With Pulsed Dye Laser Versus Topical Brimonidine 0.33% in the Treatment of Erythematotelangiectatic Rosacea: a Comparative Clinical and Dermoscopic Study

Anticipated Study Start Date :

May 25, 2022

Anticipated Primary Completion Date :

Sep 15, 2022

Anticipated Study Completion Date :

Sep 15, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Pulsed dye laser Laser	Other: treatment types
Active Comparator: Doxycycline Drug	Other: treatment types
Active Comparator: Brimonidine gel 0.33% Topical drug	Other: treatment types

Arm

Intervention/Treatment

Active Comparator: Pulsed dye laser

Laser

Other: treatment

types

Active Comparator: Doxycycline

Drug

Other: treatment

types

Active Comparator: Brimonidine gel 0.33%

Topical drug

Other: treatment

types

Outcome Measures

Primary Outcome Measures

Clinical erythema assessment scale [3 months]
clinical scale

Secondary Outcome Measures

Thickness of capillaries by dermoscope [3 months]
Assessment

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patient with current erythematotelangiectatic rosacea

Exclusion Criteria:

Pregnant females. 2-Patients on systemic steroids. 3-Patients complaining of other dermatological disorders mainly photosensitive cutaneous disorder.

4- Patients receiving any systemic treatment including retinoids for the previous 1 month or any topical treatment for the previous 2 weeks or any laser sessions for the previous 3months for erythematotelangiectatic rosacea at least.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Cairo University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Hagar El Sayed, Dr, Cairo University

ClinicalTrials.gov Identifier:

NCT05401422

Other Study ID Numbers:

Rosacea

First Posted:

Jun 2, 2022

Last Update Posted:

Jun 2, 2022

Last Verified:

Jun 1, 2022

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Rosacea

Study Results

No Results Posted as of Jun 2, 2022